Recent submissions

  • The genomic landscape of plasma cells in systemic light chain amyloidosis. 

    Boyle, EM; Ashby, C; Wardell, CP; Rowczenio, D; Sachchithanantham, S; Wang, Y; Johnson, SK; Bauer, MA; Weinhold, N; Kaiser, MF; Johnson, DC; Jones, JR; Pawlyn, C; Proszek, P; Schinke, C; Facon, T; Dumontet, C; Davies, FE; Morgan, GJ; Walker, BA; Wechalekar, AD (2018-11-16)
  • Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. 

    Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J (2015-01)
    Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ...
  • MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. 

    Ghidini, M; Hahne, JC; Frizziero, M; Tomasello, G; Trevisani, F; Lampis, A; Passalacqua, R; Valeri, N (2018-08)
    Receptor tyrosine kinases (RTKs) are widely expressed transmembrane proteins that act as receptors for growth factors and other extracellular signalling molecules. Upon ligand binding, RTKs activate intracellular signalling ...
  • Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. 

    Bisogno, G; Jenney, M; Bergeron, C; Gallego Melcón, S; Ferrari, A; Oberlin, O; Carli, M; Stevens, M; Kelsey, A; De Paoli, A; Gaze, MN; Martelli, H; Devalck, C; Merks, JH; Ben-Arush, M; Glosli, H; Chisholm, J; Orbach, D; Minard-Colin, V; De Salvo, GL; European paediatric Soft tissue sarcoma Study Group (2018-08)
    BACKGROUND: Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug ...
  • Promoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer. 

    Orlando, G; Law, PJ; Cornish, AJ; Dobbins, SE; Chubb, D; Broderick, P; Litchfield, K; Hariri, F; Pastinen, T; Osborne, CS; Taipale, J; Houlston, RS (2018-10)
    Efforts are being directed to systematically analyze the non-coding regions of the genome for cancer-driving mutations1-6. cis-regulatory elements (CREs) represent a highly enriched subset of the non-coding regions of the ...
  • Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. 

    Heindl, A; Khan, AM; Rodrigues, DN; Eason, K; Sadanandam, A; Orbegoso, C; Punta, M; Sottoriva, A; Lise, S; Banerjee, S; Yuan, Y (2018-09-25)
    How tumor microenvironmental forces shape plasticity of cancer cell morphology is poorly understood. Here, we conduct automated histology image and spatial statistical analyses in 514 high grade serous ovarian samples to ...
  • Single cell analysis of clonal architecture in acute myeloid leukaemia 

    Greaves, M; Potter, N; Miraki-Moud, F; Ermini, L; Titley, I; Vijayaraghavan, G; Taussig, D
  • Cancer cell transmission via the placenta. 

    Greaves, M; Hughes, W (2018)
    Cancer cells have a parasitic propensity in the primary host but their capacity to transit between individuals is severely restrained by two factors: a lack of a route for viable cell transfer and immune recognition in ...
  • Nothing in cancer makes sense except…. 

    Greaves, M (2018-02-21)
    Paraphrasing Dobzhansky's famous dictum, I discuss how interrogating cancer through the lens of evolution has transformed our understanding of its development, causality and treatment resistance. The emerging picture of ...
  • Many private mutations originate from the first few divisions of a human colorectal adenoma. 

    Kang, H; Salomon, MP; Sottoriva, A; Zhao, J; Toy, M; Press, MF; Curtis, C; Marjoram, P; Siegmund, K; Shibata, D (2015-11)
    Intratumoural mutational heterogeneity (ITH) or the presence of different private mutations in different parts of the same tumour is commonly observed in human tumours. The mechanisms generating such ITH are uncertain. ...
  • Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors. 

    Sottoriva, A; Vermeulen, L; Tavaré, S (2011-05-05)
    The cancer stem cell (CSC) concept is a highly debated topic in cancer research. While experimental evidence in favor of the cancer stem cell theory is apparently abundant, the results are often criticized as being difficult ...
  • A Big Bang model of human colorectal tumor growth. 

    Sottoriva, A; Kang, H; Ma, Z; Graham, TA; Salomon, MP; Zhao, J; Marjoram, P; Siegmund, K; Press, MF; Shibata, D; Curtis, C (2015-03)
    What happens in early, still undetectable human malignancies is unknown because direct observations are impractical. Here we present and validate a 'Big Bang' model, whereby tumors grow predominantly as a single expansion ...
  • Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone. 

    Piccirillo, SG; Spiteri, I; Sottoriva, A; Touloumis, A; Ber, S; Price, SJ; Heywood, R; Francis, NJ; Howarth, KD; Collins, VP; Venkitaraman, AR; Curtis, C; Marioni, JC; Tavaré, S; Watts, C (2015-01)
    Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the ...
  • Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. 

    Sottoriva, A; Spiteri, I; Piccirillo, SG; Touloumis, A; Collins, VP; Marioni, JC; Curtis, C; Watts, C; Tavaré, S (2013-03)
    Glioblastoma (GB) is the most common and aggressive primary brain malignancy, with poor prognosis and a lack of effective therapeutic options. Accumulating evidence suggests that intratumor heterogeneity likely is the key ...
  • Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. 

    Mensah, AA; Cascione, L; Gaudio, E; Tarantelli, C; Bomben, R; Bernasconi, E; Zito, D; Lampis, A; Hahne, JC; Rinaldi, A; Stathis, A; Zucca, E; Kwee, I; Gattei, V; Valeri, N; Riveiro, ME; Bertoni, F (2018-08-03)
    Aberrant changes in microRNA expression contribute to lymphomagenesis. Bromodomain and extra-terminal domain inhibitors like OTX015 (MK-8628, birabresib) have demonstrated preclinical and clinical activity in haematological ...
  • A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. 

    Bødker, JS; Brøndum, RF; Schmitz, A; Schönherz, AA; Jespersen, DS; Sønderkær, M; Vesteghem, C; Due, H; Nørgaard, CH; Perez-Andres, M; Samur, MK; Davies, F; Walker, B; Pawlyn, C; Kaiser, M; Johnson, D; Bertsch, U; Broyl, A; van Duin, M; Shah, R; Johansen, P; Nørgaard, MA; Samworth, RJ; Sonneveld, P; Goldschmidt, H; Morgan, GJ; Orfao, A; Munshi, N; Johnson, HE; El-Galaly, T; Dybkær, K; Bøgsted, M (2018-09-25)
    Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and ...
  • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. 

    Puyang, X; Furman, C; Zheng, GZ; Wu, ZJ; Banka, D; Aithal, K; Agoulnik, S; Bolduc, DM; Buonamici, S; Caleb, B; Das, S; Eckley, S; Fekkes, P; Hao, M-H; Hart, A; Houtman, R; Irwin, S; Joshi, JJ; Karr, C; Kim, A; Kumar, N; Kumar, P; Kuznetsov, G; Lai, WG; Larsen, N; Mackenzie, C; Martin, L-A; Melchers, D; Moriarty, A; Nguyen, T-V; Norris, J; O'Shea, M; Pancholi, S; Prajapati, S; Rajagopalan, S; Reynolds, DJ; Rimkunas, V; Rioux, N; Ribas, R; Siu, A; Sivakumar, S; Subramanian, V; Thomas, M; Vaillancourt, FH; Wang, J; Wardell, S; Wick, MJ; Yao, S; Yu, L; Warmuth, M; Smith, PG; Zhu, P; Korpal, M (2018-09)
    Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant ...
  • Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. 

    Pender, A; Davis, EJ; Chauhan, D; Messiou, C; Al-Muderis, O; Thway, K; Fisher, C; Zaidi, S; Miah, A; Judson, I; van der Graaf, W; Keedy, VL; Benson, C; Jones, RL (2018-08-20)
    The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following ...
  • Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. 

    Wagner, S; Vlachogiannis, G; De Haven Brandon, A; Valenti, M; Box, G; Jenkins, L; Mancusi, C; Self, A; Manodoro, F; Assiotis, I; Robinson, P; Chauhan, R; Rust, AG; Matthews, N; Eason, K; Khan, K; Starling, N; Cunningham, D; Sadanandam, A; Isacke, CM; Kirkin, V; Valeri, N; Whittaker, SR (2018-10-23)
    Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed ...
  • Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies 

    Elnenaei, MO; Jadayel, DM; Matutes, E; Morilla, R; Owusu-Ankomah, K; Atkinson, S; Titley, I; Mandala, EM; Catovsky, D (2001)
    The translocation (11;14)(q13;q32) and its molecular counterpart the BCL-1 rearrangement are features observed in mantle cell lymphoma (MCL) and less commonly in other B-cell disorders. This rearrangement leads to cyclin ...

View more